Emergent Biosolutions Inc (EBS) was Initiated by Chardan Capital Markets to “Buy” and the brokerage firm has set the Price Target at $47. Chardan Capital Markets advised their investors in a research report released on Apr 15, 2016.
Many Wall Street Analysts have commented on Emergent Biosolutions Inc. Singular Research Initiated Emergent Biosolutions Inc on Mar 28, 2016 to “Buy”, Price Target of the shares are set at $44.Emergent Biosolutions Inc was Initiated by Wells Fargo to “Outperform” on Feb 19, 2016.
On the company’s financial health, Emergent Biosolutions Inc reported $0.78 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Feb 25, 2016. Analyst had a consensus of $0.70. The company had revenue of $168.10 million for the quarter, compared to analysts expectations of $169.10 million. The company’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 EPS.
Emergent Biosolutions Inc closed down -0.54 points or -1.39% at $38.41 with 2,52,044 shares getting traded on Monday. Post opening the session at $39.18, the shares hit an intraday low of $38.25 and an intraday high of $39.3885 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Apr 8, 2016, Fuad El-hibri (Chairman) sold 50,000 shares at $39.00 per share price. According to the SEC, on Apr 8, 2016, Robert Kramer (EVP, Corporate Services Divisi) sold 21,786 shares at $38.90 per share price. On Mar 16, 2016, Jerome M Hauer (director) sold 2,350 shares at $33.88 per share price, according to the Form-4 filing with the securities and exchange commission.
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Company’s two operating divisions include Biodefense and Biosciences. The Company’s Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical Biological Radiological Nuclear and Explosives) threats. The Biodefense division’s marketed products are BioThrax; BAT; Anthrasil; VIGIV and RSDL. The Biodefense division investigational stage product candidates include NuThrax PreviThrax GC-072 and other biodefense product candidates. The Biosciences division’s marketed products are WinRho SDF HepaGam B VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY ES414 and otlertuzumab.